Module

Cytotoxic Chemotherapy in a Time of Change

Source: Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment

Cytotoxic Chemotherapy in a Time of Change

Program Chair: Alexandra M. Levine, MD

Faculty:

Julie M. Vose, MD

CME CREDIT INFORMATION

Release Date: 07/15/08

Expiration Date: 07/14/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite purine analogues used in the treatment of leukemias and lymphomas
Describe the use of alkylating agents in the treatment of patients with leukemias or lymphomas
Identify recent clinical trial data regarding antifolates in the clinical management of leukemias and lymphomas
Discuss liposomal delivery of agents used to treat lymphoproliferative disorders

Topics covered include:

Introduction
Antifolate Anticancer Agents
Cytotoxic Purine Analogues
Alkylating Agents: Monotherapy
Alkylating Agents: Combination Therapy
Alkylating Agents: Rituximab-Refractory Setting
Anthracyclines and Anthracenediones
Liposomal Nanoparticles
The Future of Cytotoxic Agents

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.